Helping scientists run complex data analyses without writing code
Co-founded by an MIT alumnus, Watershed Bio offers researchers who aren’t software engineers a way to run large-scale analyses to accelerate biology.
Co-founded by an MIT alumnus, Watershed Bio offers researchers who aren’t software engineers a way to run large-scale analyses to accelerate biology.
The Rare Brain Disorders Nexus aims to accelerate the development of novel therapies for a spectrum of uncommon brain diseases.
MIT CSAIL and McMaster researchers used a generative AI model to reveal how a narrow-spectrum antibiotic attacks disease-causing bacteria, speeding up a process that normally takes years.
MIT researchers now hope to develop synthetic versions of these molecules, which could be used to treat or prevent foodborne illnesses.
Chemotherapy-induced injury of organ tissue causes inflammation that awakens dormant cancer cells, which may cause new tumors to form.
Advance from SMART will help to better identify disease markers and develop targeted therapies and personalized treatment for diseases such as cancer and antibiotic-resistant infection.
A system conceived in Professor Michael Cima’s lab was approved by the Food and Drug Administration after positive results in patients.
Lipid metabolism and cell membrane function can be disrupted in the neurons of people who carry rare variants of ABCA7.
VaxSeer uses machine learning to predict virus evolution and antigenicity, aiming to make vaccine selection more accurate and less reliant on guesswork.
Researchers developed an approach to study where proteins get made, and characterized proteins produced near mitochondria, gaining potential insights into mitochondrial function and disease.
The team used two different AI approaches to design novel antibiotics, including one that showed promise against MRSA.
Researchers developed a tool to recreate cells’ family trees. Comparing cells’ lineages and locations within a tumor provided insights into factors shaping tumor growth.
Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.
The Fairbairn Menstruation Science Fund will allow researchers to accelerate the understanding and treatment of often-neglected diseases that tend to be more common in women.
A new approach for testing multiple treatment combinations at once could help scientists develop drugs for cancer or genetic disorders.